Cypralis is a privately held life science company specialised in the development of novel drugs based on the inhibition of cyclophilins. The company started as a spinout from Selcia Ltd. in 2012, has its headquarters at Babraham Research Park, Cambridge, UK and has raised so far £4M from private investors, grants and collaborations. The founders are experts of combined 50 years of experience in the biology of cyclophilins and the chemistry of their inhibitors. In collaboration with the Shanghai-based company Farsight Medical Technology, Cypralis is developing new first in class drugs to address unmet medical needs with an initial drug to enter clinical trials early in 2020.
Please contact us to explore opportunities for collaboration or investment.